Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122677 | 0.81 | CYP11B1 (0.36) | — | |
| SCHEMBL2120939 | 0.80 | KDM4E (0.37) | HCRTR1HCRTR2ALDH1A1L3MBTL1PDE10A | |
| SCHEMBL311517 | 0.79 | AKT1 (0.31) | — | |
| SCHEMBL2124400 | 0.77 | SMN1; SMN2 (0.36) | ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL2124331 | 0.73 | ALDH1A1 (0.40) | ALDH1A1TSHRKMT2A | |
| SCHEMBL4167672 | 0.73 | RHOC (0.38) | ALDH1A1 | |
| SCHEMBL2123540 | 0.73 | KMT2A (0.34) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL2120843 | 0.72 | MCHR1 (0.39) | ALDH1A1 | |
| SCHEMBL2120890 | 0.69 | HCRTR1 (0.33) | HCRTR1HCRTR2MEN1TSHRKMT2A | |
| SCHEMBL2122869 | 0.69 | METTL3 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | HCRTR1 2/4885HCRTR2 1/4885TRPA1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.